Junke Zheng
Overview
Explore the profile of Junke Zheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li W, Sun J, Sun R, Wei Y, Zheng J, Zhu Y, et al.
Anal Chem
. 2025 Jan;
97(2):1190-1198.
PMID: 39772508
The integrative multiomics characterization of minute amounts of clinical tissue specimens has become increasingly important. Here, we present an approach called Integral-Omics, which enables sequential extraction of metabolites, lipids, genomic...
2.
Zhang Z, Chen C, Li X, Zheng J, Zhao Y
Trends Cell Biol
. 2024 Nov;
34(11):928-941.
PMID: 39492031
Redox metabolism plays a central role in the cellular metabolism network, involves catabolic and anabolic reactions of diverse biomass, and determines the redox state of cells. It can be quantitatively...
3.
Jiang Y, Zhang D, He X, Chen C, Xie L, Liu L, et al.
Cell Oncol (Dordr)
. 2024 Oct;
PMID: 39412615
Purpose: Although most of chronic myeloid leukemia (CML) patients can be effectively treated by the tyrosine kinase inhibitors (TKIs), such as Imatinib, TKI-resistance still occurs in approximately 15-17% of cases....
4.
Xie L, Chen C, Zhang T, Yang W, Zheng D, Cao L, et al.
Cell Death Dis
. 2024 Jul;
15(7):515.
PMID: 39025844
Although multiple myeloma (MM) responds well to immunotherapeutic treatment, certain portions of MM are still unresponsive or relapse after immunotherapy. Other immune molecules are needed for the immunotherapy of MM....
5.
Wang L, Cao L, Li Z, Shao Z, Chen X, Huang Z, et al.
J Immunol
. 2024 Jun;
213(3):347-361.
PMID: 38847616
The cyclic GMP-AMP synthase (cGAS)-stimulator of IFN genes (STING) pathway is instrumental to antitumor immunity, yet the underlying molecular and cellular mechanisms are complex and still unfolding. A new paradigm...
6.
Gao R, Yuan X, Ma Y, Wei T, Johnston L, Shao Y, et al.
Cell Rep Med
. 2024 May;
5(5):101536.
PMID: 38697103
Spatial transcriptomics (ST) provides insights into the tumor microenvironment (TME), which is closely associated with cancer prognosis, but ST has limited clinical availability. In this study, we provide a powerful...
7.
Wang G, Zhang W, Ren J, Zeng Y, Dang X, Tian X, et al.
Oncogene
. 2024 Apr;
43(25):1900-1916.
PMID: 38671157
The long-term maintenance of leukaemia stem cells (LSCs) is responsible for the high degree of malignancy in MLL (mixed-lineage leukaemia) rearranged acute myeloid leukaemia (AML). The DNA damage response (DDR)...
8.
Zhao X, Cao Y, Lu R, Zhou Z, Huang C, Li L, et al.
Adv Sci (Weinh)
. 2024 Feb;
11(15):e2305541.
PMID: 38351659
Non-small-cell lung cancer (NSCLC) is a highly lethal tumor that often develops resistance to targeted therapy. It is shown that Tank-binding kinase 1 (TBK1) phosphorylates AGO2 at S417 (pS417-AGO2), which...
9.
Gu H, Chen C, Hou Z, He X, Xie S, Ni J, et al.
Blood
. 2024 Jan;
143(19):1965-1979.
PMID: 38271660
Acute myeloid leukemia (AML) is an aggressive hematological malignancy originating from transformed hematopoietic stem or progenitor cells. AML prognosis remains poor owing to resistance and relapse driven by leukemia stem...
10.
Du Y, Shi J, Wang J, Xun Z, Yu Z, Sun H, et al.
Cancer Res
. 2024 Jan;
84(2):192-210.
PMID: 38225927
Significance: Comprehensive characterization of tumor-associated nonimmune stromal cells provides a robust resource for dissecting tumor microenvironment complexity and guiding stroma-targeted therapy development across multiple human cancer types.